AvantGuard News

AvantGuard Awarded $2.65 Million in NIH Grants to Advance Next-Generation Antimicrobial Technologies

AvantGuard has been awarded a $325K NIH Phase I Grant for non-coating antimicrobial, anti-host deposition, anti-inflammatory urinary catheters. Catheter-associated urinary tract infection (CAUTI) is the most common type of healthcare-associated infection, however currently there is no effective technology to address the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field that has gained a lot of attention; however, commercial app

NEW YORK, May 11, 2023 /PRNewswire/ -- AvantGuard, a fast-growing company in the antimicrobial industry, announced today the successful...

AvantGuard, Inc. is pleased to announce a $1.7 million Phase II SBIR award from the National Institutes of Health (NIH) to continue...

ITHACA, N.Y., March 23, 2023 / PRNewswire / -- AvantGuard, announced today the unveiling of its new brand identity as a transformative "specialty chemical company" using groundbreaking antimicrobial chemistry of the N-halamine molecule to solve major disinfection and pathogen problems in the world today. The company's proprietary combination of specialty molecules offers the potential to create multiple, novel products, additives, and disinfecting methods to transform the way

(Ithaca, NY) — Halomine™, Inc. , a pioneer in advanced technology for managing surfaces and providing long term protection against...

FORT MILL, S.C., June 29, 2021 (GLOBE NEWSWIRE) - Diversey Holdings, Ltd. (NASDAQ: DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, today announced a strategic alliance with Halomine, Inc.™ and a global exclusive license agreement for their patented HaloFilmTM technology for institutional and food and beverage markets. Halomine, based in the United States, is developing a suite of game-changing, novel, long-acting, anti-microbial products wit

$77k Investment for Rollout of HaloFilm™ (Ithaca, NY) — Halomine™, a start-up company developing a suite of novel, long-acting,...

$256K Award to Study Efficacy Against Coronavirus, Other Viruses (Ithaca, NY) — Halomine™, Inc., developer of a suite of novel,...

$225K Award Recognizes “Excellent Efficacy Against Pathogens” (Ithaca, NY) — Halomine™, Inc. today announced that it has received a...